Vanta Bioscience (540729)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• Piotroski F-Score of 5/9 suggests some financial metrics are not completely broken despite operating losses.
• Reported profit growth of 12.08% shows a small bottom-line improvement, though from a loss-making base.
• Market cap of ₹33 Cr offers a large expansion runway if the business can revive revenue.
• Current price at 52-week high reflects strong speculative interest, though not fundamental confirmation.
• Industry focus on healthcare research, analytics and technology has long-term relevance if execution improves.

Concerns

• Latest quarter sales are ₹0 Cr with a net loss of ₹2 Cr, showing no active revenue engine.
• Sales growth collapsed by -70.87% and ROCE is -11.58%, indicating capital destruction.
• Book value, P/B, debt/equity and promoter holding are unavailable, leaving no margin-of-safety calculation possible.
• No dividend and a meaningless P/E of 0.00 make this a pure speculation rather than income or value investment.

AI Analysis

When I look at Vanta Bioscience, I am reminded of Graham's dictum: price is what you pay, value is what you get. At ₹51.45, the market cap is ₹33 crore, yet I have almost no tangible facts to anchor the other side of that equation. The latest quarter shows sales of ₹0 crore and a net loss of ₹2 crore. Sales growth is -70.87%. A business with no revenue and a negative bottom line is not an investment; it is a call option. Mr. Market has already pushed the stock to its 52-week high of ₹51.45 after trading as low as ₹14.71, but a rising price does not create value. With ROCE at -11.58%, the enterprise is destroying capital, not compounding it. The so-called profit growth of 12.08% is meaningless from a loss-making level. Book value, promoter holding and debt-to-equity are all blank; without these numbers I cannot compute a Graham-style safety cushion. The Piotroski score of 5/9 at least suggests the financial condition isn't as poor as it could be, but that is faint praise. There is no dividend to reward a patient shareholder. This is a speculative turnaround situation, not a proven compounder. I would need to see months of real revenue, evidence of a durable moat in healthcare research and analytics, and honest disclosure before I could consider allocating a rupee. For now, the only rational verdict is: too little information, no earnings visibility, and no margin of safety. I would rather wait for a good company at a fair price than chase a tiny, loss-making stock at its 52-week high. In Buffett's words, it's far better to be approximately right than precisely wrong; here, I am not sure I am even approximately informed.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer